In addition, clinical trial design should also take into account the positive correlation between pathologic complete response rate (pCR) with disease-free survival benefit for a subset of patients with IBC (i.e.: HER2+ IBC) as trials assessing the efficacy of neoadjuvant treatments are inherently shorter [29]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.